Project Grant R44HL180258
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$945K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Hematherix LLC, a woman-owned small business in California. The award supports the development of SuperFVa, an engineered variant of activated coagulation cofactor Factor V, as a targeted therapy to prevent and correct acute traumatic coagulopathy (ATC). ATC is characterized by diminished levels of key clotting factors, leading to...
The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, awarded a $1,249,317 Project Grant to Sanaheal Inc. for the development and validation of a "Hemostatic Bioadhesive Paste for Coagulation-Independent Rapid Control of Bleeding." The objective is to optimize and validate this hemostatic paste to meet FDA regulatory requirements in preparation for a future pivotal clinical trial and commercialization....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,963 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New Health Sciences, Inc. (Hemanext Inc.) to evaluate the hemostatic function of platelets stored under hypoxic conditions for whole blood (WB) transfusion. The project aims to develop an improved WB storage platform that maintains an oxygen-managed environment to provide higher quality red blood cells for oxygen delivery and shock reversal, while...
The U.S. Defense Health Agency awarded a $1,996,885 project grant under the Military Medical Research and Development program (CFDA 12.420) to Selsym Biotech Inc., a woman-owned small business. The funding supports the development of SYMCLOT, a synthetic platelet mimetic particle technology, to augment hemostasis for patients requiring extracorporeal support, such as those with battlefield injuries. Previous grants from the National Institutes of Health have also supported Selsym Biotech's...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,989,548.00 to Cerulean Scientific Inc., a small disadvantaged business in Durham, North Carolina, to develop a slippery, omniphobic coating for peripheral vascular grafts (PVGs). The goal is to investigate the ability of the tethered liquid perfluorocarbon (TLP) coating to resist occlusion, thrombus formation, and biofilm formation on PVGs, which are a common...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Dynaflow, Inc., a minority-owned small disadvantaged business, aims to develop a numerical platform for microbubble-enhanced sonothrombolysis. The $618,912 award, effective September 17, 2024, will fund the creation of a computational tool to accurately characterize the complex biophysics of microbubble-ultrasound interactions and their effects on blood clot lysis. This...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding the development of an innovative portable device to rapidly detect and monitor traumatic brain injury (TBI) biomarkers. The $332,122 award to Hemex Health Inc. aims to create a point-of-care diagnostic platform that can quickly analyze whole blood samples to identify elevated...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $234,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Colorado-Denver to engineer and test "hemostatic red blood cells" (T-RBCs) for the treatment of acute non-compressible hemorrhage. The key objectives are to: 1) engineer T-RBCs that bind to collagen and fibrin to enhance clot formation and stability, 2) perform in vitro testing of the T-RBCs' hemostatic properties, and 3)...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $420,600 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Colorado-Denver. The grant's objective is to design elastic hydrogel microparticles as a platform to measure key elements of platelet function, including adhesion, activation, aggregation, and contraction. This innovative "lab-on-a-particle" approach aims to improve the reliability and reproducibility of platelet function...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test for measuring anti-Factor Xa activity and hemoglobin levels. This rapid diagnostic tool is intended to guide emergency management of bleeding and strokes in patients on anti-Xa direct oral anticoagulants. The grant aims to leverage the company's existing technology, including a...